References
- Alexander, J. (2009). Health ministry to add Schedule Y1 to D&C rules to streamline clinical trials sector. Retrieved from Pharmabiz.com
- Bhatt, A. (2004). Clinical trials in India: Pangs of globalization. Indian Journal of Pharmacology, 36, 207.
- Block, M., Dhonkhar, A., & Narayanan, S. (2006, July). Pharma leaps offshore. McKinsey Quarterly.
- Bedi, N., & Bedi, P.M.S. (2013). Patenting and R&D in Indian pharmaceutical industry: Post-TRIPS scenario. Journal of Intellectual Property Rights, 18, 105–110.
- Chakraborty, B.S. (2013). Clinical Research in India: The current scenario and prospects. Journal of advanced pharmaceutical technology & research, 4, 126–127. doi:https://doi.org/10.4103/2231-4040.116776
- Chaudhuri, S. (2005). R&D for development of new drugs for neglected diseases: How can India contribute? Study prepared for WHO Commission on Intellectual Property Rights, Innovation and Public Health. Retrieved from www.who.int/intellectualproperty/studies/S.percent20Chaudhuri.pdf
- Confederation of Indian Industry (CII). (2015). Drugs & pharmaceuticals. Retrieved from http://www.cii.in/ResourceDetails.aspx?enc=ntVAHd2OGM7oyqwSWgtK6FI1EucFngwmtNvVgdhlOsYilnjYwdx4GfEuQPqyfhpJsNxWTG8sz7t8AkLQt1TCOQ==
- Cygnus. (2008). “CRAMS in India.” Cygnus Business Consulting and Research. Retrieved from http://www. cygnusindia.com/pdfs/Industry%20Insight-CRAMS-March%202008.pdf
- Davies, A., & Jones, J. (2008). Tracking CRO growth. Pharma Focus Asia, Issue 9.
- Deutsche Bank. (2006). Indian Government National Pharmaceuticals Policy, January 2006.
- Dhar, B., & Gopakumar, K.M. (2006). Post-2005 TRIPS scenario in patent protection in the pharmaceutical sector: The case of the generic pharmaceutical industry in India. The UNCTAD/ICTSD Project on Intellectual Property Rights and Sustainable Development November 2006.
- Editorial. (2007). National Pharmaceutical Policy-2006. Health Administrator, 20(1/2), 1–8.
- Felker, G. (1997). The pharmaceutical industry in India and Hungary. Washington, DC: The World Bank.
- FICCI. (2005). Competitiveness of the Indian Pharmaceutical Industry in the new product Patent Regime (FICCI Report for National Manufacturing Competitiveness Council (NMCC)). New Delhi: Federation of Indian Chambers of Commerce and Industry.
- Getz, K.A., & Vogel, J.R. (2009). Successful outsourcing: tracking global CRO usage. Applied Clinical Trials, 18, 42.
- Grace, C. (2004). The effect of changing intellectual property on pharmaceutical industry prospects in India and China (pp. 1–68). DFID Health Systems Resource Centre.
- Greene, W. (2007). The emergence of India’s pharmaceutical industry and implications for the U.S. generic drug market. U.S. International Trade Commission.
- Huang, Y., & Khanna, T. (2003). Can India overtake china? Foreign Policy, (137), 74. doi:https://doi.org/10.2307/3183699
- ICRA. (2011). CRAMS India: Overlook and outlook. Retrieved from www.icra.in/Files/Articles/CRAMSpercent20Note,percent20Overviewpercent20andpercent20Outlook.pdf
- Indian Brand Equity Foundation (IBEF). (2017). Pharmaceuticals, India. Retrieved from www.ibef.org
- Joseph, R.K. (2011). The R&D scenario in the Indian pharmaceutical industry. RIS Discussion Paper No. 176. Retrieved from http://ssrn.com/abstract =2009229 or http://dx.doi.org/10.2139/ssrn.2009229
- Joseph, R.K. (2015). Pharmaceutical industry and public policy in post-reform India. Routledge.
- Kamble, P., Ghorpade, S., Kshirsagar, R., & Kuchekar, B. (2012). Progress of the Indian pharmaceutical industry: a shifting perspective. Journal of Intellectual Property Law & Practice, 7, 48–51. doi:10.1093/jiplp/jpr177
- Kiran, R., & Mishra, S. (2011). Research and development, exports and patenting in the Indian pharmaceutical industry: a post TRIPS analysis. Eurasian Journal of Business and Economics, 4, 53–67. Retrieved from www.marketresearch.com/Espicom-Healthcare-Intelligence-v1129/Pharmaceutical-India-6974817/
- KPMG. (2006). The Indian pharmaceutical industry: Collaboration for growth. Retrieved from https://www.kpmg.de/media/20060501_The_Indian_pharmaceutical__industry.pdf
- KPMG. (2016). Pharmaceuticals: Union Budget 2016–Budget sectoral point of view. Retrieved from https://home.kpmg.com/content/dam/kpmg/pdf/2016/04/LS-Budget-2016-PoV.pdf
- Krishnan, S. & Hatekar, N. (2017 June). Rise of the new middle class in India and its changing structure. Economic and Political Weekly, 52. Retreived August 10, 2017, from http://www.epw.in/journal/2017/22/special-articles/rise-new-middle-class-india-andits-changing-structure.html
- Kumar, V. (2007). India: An emerging knowledge superpower. Pharmaceutical Executive, 36, S17. Retrieved from www.pharmexec.com/india-emerging-knowledge-superpower?id=&sk=&date=&%0A%09%09%09&pageID =10
- Mathew, J.C. (2009, March 6). USFDA door wide open for Indian pharma cost. Business Standard.
- McKinsey. (2012). India Pharma 2015: Unlocking the potential of the Indian Pharmaceutical Market. Retrieved from http://casestudies10.weebly.com/uploads/9/0/0/2/9002260/india_pharma_2015.pdf
- McKinsey Global Institute. (2007). Indian Pharma 2020: Propelling access and acceptance, realizing true potential. Retrieved from www.mckinsey.com/∼/media/mckinsey%20offices/india/pdfs/india_pharma_2020_propelling_access_and_acceptance
- Ministry of Health and Family Welfare Government of India (MHFW). (2005). Financing and Delivery of Health Care Services in India. New Delhi: Government of India.
- Mitra, R.M. (2006). India’s emergence as a global R&D center. Stockholm: Swedish Institute for Growth Policy Studies. Unpublished.
- Mohiuddin, M., & Su, Z. (2013a). Manufacturing small and medium size enterprises offshore outsourcing and competitive advantage: An exploratory study on Canadian offshoring manufacturing SMEs. Journal of Applied Business Research, 29, 1111–1130. doi:10.19030/jabr.v29i4.7920
- Mohiuddin, M., & Su, Z. (2013b). Offshore outsourcing of core and non-core activities and integrated firm-level performance: An empirical analysis on Québec manufacturing SMEs. M@n@gement, 16, 454–478.
- Mohiuddin, M., & Su, Z. (2014). Global value chain and competitiveness of Canadian manufacturing SMEs. Academy of Taiwan Business Management Review, 10, 82–92.
- Mohiuddin, M. (2011). Research on offshore outsourcing: A systematic literature review. Journal of International Business Research, 10, 57–76.
- National Commission on Macroeconomics and Health of India (NCMHI). (2005). Report of the National Commission on Macroeconomics and Health. New Delhi: Ministry of Health & Family Welfare, Government of India.
- Pasha, M.S., Ehtesham, M., Riaz, M.N.A, Khan, M.T.A., & Zuber, M. (2012). A new pharmaceutical environment in India: Marketing impacts. International Journal of Phytopharmacology, 3, 32–35.
- PricewaterhouseCoopers (PwC). (2011). Global Pharma looks to India: Prospects for growth. Retrieved from http://www.pwc.com/gx/en/pharma-life-sciences/pdf/global-pharma-looks-to-india-final.pdf
- Rao, P.M. (2008). The emergence of the pharmaceutical industry in the developing world and its implications for multinational enterprise strategies. International Journal of Pharmaceutical and Healthcare Marketing, 2, 103–116. doi:10.1108/17506120810887907
- Ray, A.S. (2008). Learning and innovation in the Indian pharmaceutical industry: the role of IPR and other policy interventions. Electronic Journal of Communication, Information & Innovation in Health, 2, 71–77. doi:https://doi.org/10.3395/reciis.v2i2.192en
- Reserve Bank of India (RBI). (2016). Handbook of statistics on the Indian economy. Retrieved from RBI Database.
- Sachs, G. (2007). BRICs and beyond. London: The Goldman Sachs Group/Global Economics Department.
- Sampath, G. (2006). Economic aspects of access to medicines after 2005: Product patent protection and emerging firm strategies in the Indian pharmaceutical industry. United Nations University–Institute for New Technologies (INTECH).
- Satyanarayana, K., Sharma, A., Parikh, P., Vijayan, V.K., Sahu, D.K., Nayak, B.K. … & Sreehari, U. (2008). Statement on publishing clinical trials in Indian biomedical journals. Indian Journal of Pediatrics, 75, 755–755. doi:10.1007/s12098-008-0145-z
- Smith, S.E. (2000). Opening up to the World: India’s pharmaceutical companies prepare for 2005. Stanford, CA: Asia Pacific Research Center, Institute for International Studies, Stanford University. Retrieved from http://APARC.stanford.edu
- Srinivasan, S. & Nikarge, S. (2009). Ethical Concerns in Clinical Trials in India: An investigation. Mumbai: Centre for Studies in Ethics and Rights.
- Tempest, B. (2011). The structural changes in the global pharmaceutical marketplace and their possible implications for intellectual property. UNCTAD-ICTSD Project on IPRs and Sustainable Development; Policy Brief No. 10. Geneva: International Centre for Trade and Sustainable Development. Retrieved from www.ictsd.org
- The Patents (Amendment) Act. (2005). Retrieved from www.patentoffice.nic.in/ipr/patent/patent_2005.pdf
- The Patents Act. (1970). Office of the Controller General of Patents, Designs, and Trademarks, Government of India.